Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002, for eXegenics Inc. (Note: The input metadata lists "OPKO HEALTH, INC.", but the filing text explicitly identifies the issuer as "EXEGENICS INC." and references its Delaware incorporation and IRS number). The company is a post-genomics drug creation enterprise focusing on cancer and drug-resistant bacterial diseases. During the period, the company restructured operations to concentrate on strategic drug discovery programs following the completion of a major funding agreement with Bristol-Myers Squibb (BMS).
Key Financial Metrics
| Metric | Six Months Ended June 30, 2002 | Six Months Ended June 30, 2001 |
|---|---|---|
| Revenue | $556,000 | $667,000 |
| Net Loss (Attributable to Common) | $(3,822,000) | $(4,468,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.24) | $(0.28) |
| Cash and Cash Equivalents (End of Period) | $12,170,000 | $10,632,000 |
| Total Investments | $10,027,000 | $10,050,000 |
| Total Current Assets | $22,618,000 | $26,251,000 |
| Total Current Liabilities | $918,000 | $1,302,000 |
| Net Cash Used in Operating Activities | $(3,462,000) | $(3,309,000) |
Material Changes Versus Prior Period
- Revenue Decline: Revenue decreased by 17% ($111,000) year-over-year, driven by the cessation of milestone payments from the BMS agreement, which concluded in February 2002.
- Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) expenses fell 18% ($530,000) and General and Administrative (G&A) expenses fell 22% ($599,000). These reductions were achieved through the discontinuation of non-strategic projects, employee terminations, and reduced professional fees.
- Improved Loss Position: Despite lower revenue, the net loss attributable to common shareholders decreased by 14% ($646,000) due to the aggressive cost-cutting measures.
- Interest Income: Interest income dropped 55% ($457,000) due to lower interest rates and reduced principal balances.
Guidance, Outlook, and Risks
- Strategic Pivot: The company is shifting focus to leveraging proprietary technologies (QCT and OASIS) to create novel compounds for anti-infective and anti-cancer treatments. It is also exploring mergers or acquisitions of later-stage pharmaceutical compounds.
- Liquidity Outlook: Management believes current cash and investment balances (~$22.2 million) are sufficient to fund operations for the next twelve months. However, the company has lost its sole source of revenue (BMS funding) and cannot assure future revenue generation.
- Restructuring: The company recognized approximately $560,000 in restructuring costs through June 30, 2002, related to employee terminations and facility changes.
- Nasdaq Compliance Risk: The company received notice from Nasdaq that its stock price closed below the $1.00 minimum bid price for 30 consecutive trading days. It has 90 days (until October 23, 2002) to regain compliance or face potential delisting.
- Collaboration Changes: The agreement with the Research and Development Institute (RDI) was terminated, relieving the company of future minimum royalty payments. Discussions with BMS regarding commercialization of the paclitaxel process are ongoing.
Key Facts for Investor Verification
- Revenue Dependency: Verify the status of new licensing or partnership agreements, as the company currently has no active revenue-generating contracts following the BMS funding conclusion.
- Delisting Risk: Monitor the stock price to ensure it meets the $1.00 bid price requirement for 10 consecutive days before October 23, 2002, to avoid delisting from the Nasdaq National Market.
- Cash Burn Rate: Confirm the sustainability of the ~$3.5 million semi-annual operating cash burn against the ~$22.2 million cash and investment balance.
- Acquisition Strategy: Assess the progress of the company's search for merger or acquisition targets to accelerate its drug pipeline.
- Patent Status: Verify the status of the provisional patent application filed in April 2002 for the new chemical entities (NCEs) targeting Gram-positive bacteria.